NewEdge Wealth LLC Takes $682,000 Position in Zimmer Biomet Holdings, Inc. $ZBH

NewEdge Wealth LLC acquired a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 3rd quarter, HoldingsChannel reports. The institutional investor acquired 6,923 shares of the medical equipment provider’s stock, valued at approximately $682,000.

Several other institutional investors and hedge funds have also bought and sold shares of ZBH. Brighton Jones LLC bought a new position in shares of Zimmer Biomet in the fourth quarter worth $204,000. Sivia Capital Partners LLC bought a new position in Zimmer Biomet in the 2nd quarter worth about $232,000. United Bank increased its stake in Zimmer Biomet by 10.7% in the 2nd quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock worth $1,085,000 after acquiring an additional 1,153 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Zimmer Biomet by 1.1% during the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 507,032 shares of the medical equipment provider’s stock valued at $46,246,000 after acquiring an additional 5,317 shares during the last quarter. Finally, Focus Partners Advisor Solutions LLC boosted its position in shares of Zimmer Biomet by 128.8% during the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 4,473 shares of the medical equipment provider’s stock valued at $408,000 after acquiring an additional 2,518 shares during the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Price Performance

ZBH stock opened at $99.39 on Tuesday. The firm has a market cap of $19.70 billion, a P/E ratio of 28.08, a P/E/G ratio of 2.02 and a beta of 0.62. The firm’s fifty day moving average is $90.78 and its 200 day moving average is $95.89. Zimmer Biomet Holdings, Inc. has a 52 week low of $84.59 and a 52 week high of $114.44. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.38 by $0.04. The business had revenue of $2.24 billion during the quarter, compared to analyst estimates of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The company’s revenue was up 10.9% on a year-over-year basis. During the same period in the prior year, the business posted $2.31 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s payout ratio is 27.12%.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on ZBH shares. UBS Group restated a “sell” rating and issued a $89.00 price objective on shares of Zimmer Biomet in a research report on Wednesday, February 11th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a report on Tuesday, February 10th. Weiss Ratings restated a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Wednesday, January 21st. Johnson Rice set a $112.00 target price on shares of Zimmer Biomet in a research report on Wednesday, November 5th. Finally, William Blair initiated coverage on Zimmer Biomet in a research report on Friday. They set a “market perform” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus target price of $106.20.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.